Summary of Phathom Pharmaceuticals FY Conference Call Company Overview - **Company**: Phathom Pharmaceuticals (NasdaqGS:PHAT) - **Product**: VOQUEZNA, a first-in-class potassium-competitive acid blocker for treating gastroesophageal reflux disease (GERD) [2][3] Financial Performance - **2025 Revenue**: $175.1 million, up from $55 million in 2024 [3][4] - **2026 Revenue Guidance**: Expected to be between $320 million and $345 million, indicating a growth of over $140 million from 2025 [4][25] - **Operating Profitability**: Expected in the second half of 2026, with positive free cash flow anticipated from 2027 [4][27] - **Cash Usage**: Significant reduction in cash usage from $85 million in Q1 2025 to $5 million in the last quarter [24] Market Opportunity - **Target Market**: 22 million patients treated with prescription PPIs annually, with 40% still experiencing symptoms [5][6] - **Potential Revenue**: Estimated $1 billion opportunity in GI practices and another $1 billion in primary care [7][17] - **Prescription Growth**: 273,000 scripts last quarter, with a target of 4-6 million prescriptions per year to reach $1 billion in revenue [14][15] Product Advantages - **Mechanism of Action**: VOQUEZNA offers rapid, potent, and durable pH elevation, providing better relief for patients inadequately treated by PPIs [8][9] - **Patient Journey**: Focus on patients who have failed PPI therapy and are experiencing significant pain, leading to referrals to gastroenterologists [10][11] Sales Strategy - **Sales Organization Realignment**: Shifted focus to GI practices, with 70% of sales calls now targeting GI specialists [12][13] - **Top Prescribers**: The top 300 GI writers have converted about 20% of their prescriptions to VOQUEZNA, with plans to expand this rate across the GI community [18] Regulatory and Competitive Landscape - **IP and Exclusivity**: VOQUEZNA has a 10-year exclusivity under the GAIN Act, preventing generic entry until May 2032 [29][30] - **Market Assessment for OTC**: Exploring potential for over-the-counter sales post-2033, but currently focused on prescription market [36] Patient Retention and Feedback - **Prescription Persistence**: Majority of patients fill multiple prescriptions, with an average of 6-7 refills in the first year [33] - **Feedback Loop**: Importance of physician feedback from patients to drive adoption and confidence in prescribing VOQUEZNA [38][39] Conclusion - **Growth Trajectory**: Phathom Pharmaceuticals is on a solid growth trajectory with a clear path to profitability, focusing on the GI market and leveraging the unique advantages of VOQUEZNA to capture significant market share [28]